PF-00562271 化学構造
分子量: 665.66



Quality Control & MSDS


  • Compare FAK Inhibitors
  • 研究分野
  • PF-00562271のメカニズム



製品説明 PF-00562271は、焦点粘着力キナーゼ(FAK)とPyk2触媒活性の強力な、ATP競争的、可逆的な阻害剤で、IC50 がそれぞれ 1.5 nM と 14 nMです。
ターゲット FAK Pyk2
IC50 1.5 nM 14 nM [1]
In vitro試験 PF-562271 shows the selective inhibitory effects on FAK and Pyk2 tyrosine kinase activity with IC50 of 1.5 nM and 14 nM, respectively. And in cell-based assays, the IC50 of PF-562271 is shown to be 5 nM for FAK, which is more selective compared to other kinase targets. [1] In 2 dimensional (2D) cultures, PF-562271 results in a dose-dependent cell proliferation inhibition in FAK WT, FAK−/− and FAK kinase-deficient (KD) cells with IC50 of 3.3 μM, 2.08 μM and 2.01 μM, respectively. [2]
In vivo試験 In several human s.c. xenograft models, PF-562271 exhibits dose-dependent tumor growth inhibition, and produces maximum tumor inhibition for PC-3M, BT474, BxPc3, and LoVo ranging from 78% to 94% inhibition at doses of 25 to 50 mg/kg twice daily, without weight loss, morbidity, or death. [1] PF-562271 (25 mg/kg by p.o.) leads to a significant decrease in tumor progression in both subcutaneous and bone metastasis PC3M-luc-C6 xenograft models. [3] In a Huh7.5 hepatocellular carcinoma xenograft model, combination therapy of sunitinib and PF-562271 targets angiogenesis and tumor aggressiveness, and produces more significant anti-tumor effect than single agent by blocking tumor growth and impacting the ability of the tumor to recover upon withdrawal of the therapy. [4]

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Recombinant kinase assay and enzyme kinetics Briefly, purified-activated FAK kinase domain (amino acid 410–689) is reacted with 50 μM ATP and 10 μg per well of a random peptide polymer of Glu and Tyr, p(Glu/Tyr), in kinase buffer [50 mM HEPES (pH 7.5), 125 mM NaCl, and 48 mM MgCl2] for 15 minutes. Phosphorylation of p(Glu/Tyr) is challenged with serially diluted PF-562271 at 1/2-Log concentrations starting at a top concentration of 1 μM. Each concentration is tested in triplicate. Phosphorylation of p(Glu/Tyr) is detected with a general antiphospho-tyrosine (PY20) antibody followed by horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody. HRP substrate is added, and absorbance readings at 450 nm are obtained after addition of stop solution (2 M H2SO4). IC50 values are determined using the Hill-Slope Model. Broad kinase selectivity profiling is performed in house and by using the KinaseProfiler Selectivity Screening Service available through UpState Biotechnology.

細胞アッセイ: [2]

細胞株 Squamous cell carcinoma (SCC)
濃度 0 to 1 μM
反応時間 72 hours
実験の流れ Cells are plated for 48 hours before addition of PF-562271. After 3 days cells are fixed by addition of ice cold 25% trichloroacetic acid (TCA) solution prior to staining with Sulforhodamine B (SRB) dye solution. Plates are washed with 1% glacial acetic acid, air-dried and resuspended in 10 mM Tris buffer, pH 10.5 before reading absorbance at 540 nm. Curve fitting and generation of IC50 values is carried out using GraphPad Prism 4 software from six replicates.

動物実験: [1]

動物モデル PC-3M, BT474, BxPc3, LoVo, U87MG, H125 and H460 cells are injected s.c. into the right flank of athymic female mice .
製剤 PF-562271 is dissolved in 5% Gelucire.
投薬量 ≤100 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download PF-00562271 SDF
分子量 665.66


CAS No. 939791-38-5
保管 2年-20℃
6月-80℃in solvent
別名 PF-562271 Besylate
溶解度 (25°C) * In vitro DMSO 14 mg/mL warmed (21.03 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-methyl-N-(3-((2-(2-oxoindolin-5-ylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)methyl)pyridin-2-yl)methanesulfonamide benzenesulfonate

カスタマーフィードバック (1)

Click to enlarge
Source Mol Ther, 2012, 20(5), 972-83. PF-00562271 purchased from Selleck
Method rAAV-luciferase transduction assay
Cell Lines Fibroblasts and HeLa cells
Concentrations 1 uM
Incubation Time 24 h
Results Pharmacologic inhibition of FAK kinase activity with PF-00562271 blocked Mn <SUP>++</SUP> -induced transduction, confirming that the effect of Mn <SUP>++</SUP> requires FAK kinase activity.

文献中の引用 (1)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related FAK 阻害剤

  • PND-1186 (VS-4718)

    PND-1186 (VS-4718) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. Phase 1.

  • PF-431396

    PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • TAE226 (NVP-TAE226)

    TAE226 (NVP-TAE226)、強力な二重FAK/IGF-IR、 FAK とIGF-IRを妨げて、IC50 がそれぞれ 5.5 nM と 0.14 μMです。

  • PF-562271

    PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

  • PF-573228

    PF-573228 は FAKの阻害剤で、IC50 が 4 nMです。

  • PF-562271 HCl

    PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765)は、0.5nMのIC50による有力で非常に選択的なブラットンのチロシン・キナーゼ(Btk)阻害剤です。


Tags: PF-00562271を買う | PF-00562271供給者 | PF-00562271を購入する | PF-00562271費用 | PF-00562271生産者 | オーダーPF-00562271 | PF-00562271代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID